Equities

Frontier Biotechnologies Inc

688221:SHH

Frontier Biotechnologies Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)6.60
  • Today's Change0.07 / 1.07%
  • Shares traded2.14m
  • 1 Year change-44.44%
  • Beta--
Data delayed at least 15 minutes, as of May 17 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Frontier Biotechnologies Inc is a China-based company engaged in research and development, production and sales of innovative drugs. The Company's products include Aikening and Combination regiment of Albuvirtide (ABT) + 3BNC117 which is during clinical stage for treatment of human immunodeficiency virus (HIV). Its clinical-stage products also include transdermal analgesic patch AB001 for treating muscle, skeleton and joint pain. The Company conducts its businesses within the China market and to overseas markets.

  • Revenue in CNY (TTM)126.99m
  • Net income in CNY-308.96m
  • Incorporated2013
  • Employees395.00
  • Location
    Frontier Biotechnologies IncHi-Tech Park, Jiangning DistrictNANJING 211199ChinaCHN
  • Phone+86 2 569648375
  • Fax+86 2 569748373
  • Websitehttp://www.frontierbiotech.com
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Xinjiang Bai Hua Cun Pharma Tech Co Ltd384.44m26.95m2.33bn787.0086.323.20--6.070.07080.07081.011.910.3671.381.79488,492.202.57-4.593.60-6.2448.3829.547.01-18.401.44--0.0021--5.54-2.50137.33---21.00--
Frontier Biotechnologies Inc126.99m-308.96m2.47bn395.00--1.92--19.47-0.8248-0.82480.3393.440.05751.403.00321,484.60-13.99-14.05-16.25-15.7830.102.35-243.30-450.082.86--0.2347--34.82126.637.79--28.13--
Beijing Succeeder Technology Inc284.54m120.76m2.62bn296.0021.681.61--9.201.141.142.6815.360.17112.399.52961,290.607.267.777.638.2562.4861.0342.4338.3414.58--0.0000722.2220.406.6012.2915.5799.03--
Ginwa Enterprise Group Inc572.93m-23.61m2.63bn553.00--1.63--4.59-0.0633-0.06331.534.320.29884.745.641,036,046.00-1.230.3641-1.440.414175.6073.64-4.121.153.330.34390.0206124.25-2.41-5.37-228.19--61.66--
Novoprotein Scientific Inc136.28m-927.60k2.63bn579.00--1.20--19.28-0.0132-0.01321.9431.190.05850.44931.67235,364.30-0.0398---0.0409--70.17---0.6807--34.49--0.0353---42.09---85.84------
Data as of May 17 2024. Currency figures normalised to Frontier Biotechnologies Inc's reporting currency: Chinese Yuan Renminbi CNY

Institutional shareholders

7.38%Per cent of shares held by top holders
HolderShares% Held
Nuode Asset Management Co., Ltd.as of 21 Mar 20234.81m2.34%
UBS Asset Management Switzerland AGas of 21 Mar 20234.63m2.25%
China Asset Management Co., Ltd.as of 30 Sep 20222.80m1.36%
AEON Insurance Asset Management Co., Ltd.as of 21 Mar 2023740.19k0.36%
Western Leadbank Fund Management Co., Ltdas of 31 Dec 2023719.31k0.35%
Harvest Fund Management Co., Ltd.as of 31 Dec 2023473.42k0.23%
Da Cheng Fund Management Co., Ltd.as of 31 Dec 2023420.00k0.20%
China Southern Asset Management Co., Ltd.as of 30 Jun 2023315.00k0.15%
E Fund Management Co., Ltd.as of 31 Dec 2023235.77k0.12%
Bosera Asset Management Co., Ltd.as of 30 Jun 202330.44k0.02%
More ▼
Data from 09 Jun 2023 - 16 May 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.